Thyrocare Technologies Limited (BOM:539871)
India · Delayed Price · Currency is INR | Market Cap | 83.08B +59.3% |
| Revenue (ttm) | 8.29B +20.6% |
| Net Income | 1.63B +78.2% |
| EPS | 10.24 +78.3% |
| Shares Out | 159.17M |
| PE Ratio | 50.97 |
| Forward PE | 47.34 |
| Dividend | 9.33 (1.79%) |
| Ex-Dividend Date | Oct 24, 2025 |
| Volume | 27,149 |
| Open | 519.95 |
| Previous Close | 522.10 |
| Day's Range | 500.00 - 523.30 |
| 52-Week Range | 292.42 - 537.97 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 600.00 (+14.95%) |
| Earnings Date | May 7, 2026 |
About Thyrocare Technologies
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the bran... [Read more]
Financial Performance
In fiscal year 2026, Thyrocare Technologies's revenue was 8.29 billion, an increase of 20.61% compared to the previous year's 6.87 billion. Earnings were 1.63 billion, an increase of 78.18%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for 539871 stock is "Strong Buy." The 12-month stock price target is ₹600.00, which is an increase of 14.95% from the latest price.
News
Thyrocare shares jump over 11% after Q4 results; Net profit surges 117% to Rs 47.1 crore, revenue up 19.7%
Shares of Thyrocare Technologies surged 11% in Friday’s trade after the company reported strong consolidated Q4FY26 earnings, driven by robust growth in profit, revenue, and operating margins. As of 9...
Thyrocare Technologies receives Rs 2 crore tax demand notice for FY 2024-25
Thyrocare Technologies has received a demand notice from the Income Tax Department, raising a tax demand of ₹2,02,82,260 for the assessment year 2024-25. The notice, dated 27 March 2026, was…
Thyrocare Technologies shares fall sharply over 4% today despite strong Q3 FY26 results
Shares of Thyrocare Technologies declined sharply by over 4% in early morning trade, even as the diagnostics major reported a...
Thyrocare shares jump over 11% after strong Q2 results; Approves bonus issue in 2:1 ratio
Thyrocare Technologies shares rallied more than 11% in morning trade after the company announced its quarterly results for the July–September...
Thyrocare Technologies Q2 Results: Revenue soars 22% YoY to Rs 216.5 crore, net profit up 79%
Thyrocare Technologies, one of India’s leading diagnostic and preventive healthcare service providers, reported strong growth in its Q2 FY26 financial...
Thyrocare shares rally over 7% as Q1 net profit rises 62% YoY Rs 38.06 crore, revenue up 23% YoY
Shares of Thyrocare Technologies surged more than 7% in early trade after the company posted a solid set of numbers for the June quarter of FY26, driven by double-digit growth in both revenue and prof...
Thyrocare Technologies Q1 Results: Net profit jumps 62% YoY Rs 38.06 crore, revenue up 23% YoY
Thyrocare Technologies Limited, one of India’s leading diagnostic service providers, has announced strong financial results for the quarter ended June 30, 2025 (Q1FY26). The company reported a 23% yea...
Thyrocare Technologies Q4 results: Revenue up 21% YoY to Rs 187.2 crore, PAT jumps 88% YoY; Board recommends Rs 21 dividend per share
Thyrocare Technologies Limited has recommended a final dividend of ₹21 per equity share for FY25, subject to approval by shareholders at the ensuing AGM. This announcement comes as the company posts a...
Thyrocare Technologies Q3 FY25 Results: Revenue jumps 23.2% YoY to Rs 165.9 crore, Net Profit surges 24% YoY
Thyrocare Technologies has delivered a strong performance in the third quarter of FY25, reporting notable growth across key financial metrics. The company’s net profit surged by 24% year-on-year (YoY)...
Thyrocare completes acquisition of Vimta Labs’ Diagnostic business
Thyrocare Technologies Limited has successfully completed the acquisition of the diagnostic and pathological services business of Vimta Labs Limited. The acquisition was finalized on October 11, 2024,...